Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer

NCT07637513 | Not Yet Recruiting Phase 3 DMC FDA Drug

• 2 other identifiers: PrE0512Amgen 20240331
• Study Type: interventional
• Target: 430
• Locations: 0 countries
• Sites: N/A

Brief Summary

Eligible participants with limited stage-small cell lung cancer (LS-SCLC) will be enrolled after completion of chemotherapy and radiation. Participants will be randomized to either tarlatamab in combination with durvalumab or durvalumab alone as consolidation therapy. Treatment will continue until disease progression, unacceptable side effects or withdrawal of consent. Tarlatamab is a targeted cancer treatment. It works by acting as a matchmaker between the immune system's T-cells and the cancer cells, forcing them to come together so the T-cells can attack the cancer. Image testing will be done standardly during treatment. These tests show whether the cancer has progressed and if further treatment may be needed. The purpose of this trial is to evaluate how well the treatment works (how long before your cancer comes back and how long you live).

Conditions

Limited Stage Small-Cell Lung Cancer

Keywords

Tarlatamab; Durvalumab; Consolidation; Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (2)

• This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).

  The dual primary endpoints are PFS by Blinded Independent Central Review (BICR) and OS. OS is defined as time from randomization until death due to any cause.

  From randomization until death due to any cause, assessed up to 131 months.

• This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).

  The dual primary endpoints are PFS by Blinded Independent Central Review (BICR) and OS. PFS is defined as the time from randomization until the first documentation of radiologic disease progression or death due to any cause, whichever occurs first, in the absence of subsequent anticancer therapy. For participants with post-baseline imaging assessments, PFS will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anticancer therapy or the earlier of the following, where applicable: (a) the last evaluable post-baseline tumor assessment prior to or on subsequent anticancer therapy, or (b) the last post-baseline assessment that precedes two or more consecutive missing/not evaluable assessments followed by disease progression or death. For participants with no post-baseline imaging assessments, PFS will be censored at the date of randomization.

  From randomization until the first documentation of radiologic disease progression or death due to any cause, whichever occurs first, assessed up to 131 months.

Secondary Outcomes (5)

• Secondary endpoints include safety/tolerability.

  From treatment start to 90 (+5) days after their last dose of study medication.

• Secondary endpoints include investigator-assessed PFS.

  From randomization until the first documentation of investigator-assessed radiologic disease progression or death due to any cause, whichever occurs first, assessed up to 131 months.

• Secondary endpoints 3 and 5-year PFS rate

  From randomization to 3 and 5 years after randomization.

• Secondary endpoints include 3 and 5-year OS rate.

  From randomization to 3 and 5 years after randomization.

• Secondary endpoints include cumulative incidence Central Nervous System (CNS) metastases.

  From randomization until last follow-up, assessed up to 131 months.

Study Arms (2)

Arm A: Tarlatamab in Combination with Durvalumab

EXPERIMENTAL

Tarlatamab in combination with durvalumab. 1 cycle = 28 days.

Drug: Tarlatamab; Drug: Durvalumab

Arm B: Durvalumab

ACTIVE COMPARATOR

Durvalumab only. 1 cycle = 28 days.

Drug: Durvalumab

Interventions

Durvalumab DRUG

Durvalumab 1500 mg IV: Every 4 weeks until disease progression, unacceptable toxicity, or a maximum of 24 months from cycle 1 day 1, unless other treatment discontinuation criteria are met.

Also known as: MEDI4736, IMFINZI®

Arm A: Tarlatamab in Combination with Durvalumab; Arm B: Durvalumab

Tarlatamab DRUG

Tarlatamab Intravenous (IV): Cycle 1 Step Dose: Day 1- 1 mg; Day 8- 10 mg; Day 15- 10 mg of a 28-day cycle, then Cycle 2 and Subsequent Cycles: Day 1- 10 mg and Day 15- 10 mg every 28-day cycle up to 12 months from cycle 1 day 1 unless other treatment discontinuation or rechallenge criteria are met.

Also known as: AMG 757, IMDELLTRA

Arm A: Tarlatamab in Combination with Durvalumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

* Patient must have histologically or cytologically confirmed Small Cell Lung Cancer (SCLC). * SCLC must be diagnosed as Limited-Stage-SCLC (LS-SCLC) (Stage I-III, disease can be encompassed within a radical radiation portal per investigator assessment) and treated with 3 to 4 cycles of chemotherapy and radiation therapy. Three cycles of chemotherapy will be acceptable if the planned radiation therapy course is completed concurrently with chemotherapy. * Patient must not be eligible for surgical resection or have had prior surgical resection for the current diagnosis of LS-SCLC. * Small cell carcinoma may not be transformed from previous diagnosis of non-small cell lung cancer (e.g., Epidermal Growth Factor Receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with SCLC transformation). Mixed histology (aka combined small cell) histology tumors are permitted if the majority component is small cell histology. * Chemotherapy must consist of a platinum agent (carboplatin or cisplatin) and etoposide. * Definitive radiation may include daily treatment ≥ 60 gray (Gy) or twice-daily treatments 45 Gy or other biologically equivalent regimens given concurrently with chemotherapy. * For early LS-SCLC (e.g., T1-2, N0, M0) without lymph node involvement, treatment with stereotactic ablative radiotherapy (SABR/SBRT) and chemotherapy is allowed. * Prophylactic cranial radiation (PCI) is permitted but not required. If PCI is administered, 7 day wash-out period is required before start of study treatment. * PCI consists of whole brain radiation therapy delivered in the absence of brain metastases. Hippocampal-sparing whole brain plans are considered PCI. * Patient must be able to be randomized and have planned cycle 1 day 1 treatment within 42 days of the last dose of thoracic radiation therapy or end of last cycle of chemotherapy, whichever was given most recently. * Completed chemotherapy and radiation with no evidence of progression of disease per Response Evaluation Criteria for Solid Tumors (RECIST) v1.1 (i.e., achieved complete response, partial response, or stable disease), including no evidence of metastatic disease on brain MRI, after treatment but prior to randomization. * Patient must be ≥ 18 years of age. * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Patient must have the ability to understand and willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible. * Patient must be willing to provide archived tumor tissue (if available) for research. * Patient must have adequate organ function and marrow function as defined below, obtained ≤ 14 days prior to randomization (Echocardiogram (ECHO)/Multi-Gated Acquisition (MUGA) ≤ 28 days). * Absolute Neutrophil Count (ANC) ≥ 1500/microliter (mcL) * Hemoglobin ≥ 8.0 g/dL * Platelets ˃100,000/mcL * Prothrombin time (PT)/international normalized ratio (INR) ≤ 1.5x upper limit normal (ULN) except for patients on stable dose anticoagulation for 6 weeks prior to randomization. * Activated partial thromboplastin Time (aPTT) ≤ 1.5x ULN except for patients on stable dose anticoagulation for 6 weeks prior to randomization. * Serum Creatinine ≤ 2x ULN * Creatinine clearance(CrCl) ≥ 30 mL/min * ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase) ≤ 2.5x ULN * Total Bilirubin ≤ 1.5x ULN or ≤ 2x ULN for patients with documented Gilbert's disease * No evidence of human immunodeficiency virus (HIV) within 6 months of randomization. * Hepatitis B virus (HBV) and Hepatitis C virus (HCV) negative within 6 months of randomization. * Pulmonary Function: No oxygen supplementation * Electrocardiogram (ECG) with no findings of acute/subacute ischemia and/or clinically significant arrythmia * Cardiac Function: Cardiac ejection fraction ≥ 50% and no large or symptomatic pericardial effusion requiring intervention * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. * Patient must not expect to conceive, or father children by using an accepted and highly effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study, and for 90 days after the last dose of study drug(s). Also, patient must not expect to breastfeed, donate eggs, or donate sperm during study or for 90 days after the last dose of study drug(s). * Patient with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * Patient must not have had major surgery within 28 days, or minor surgery within 10 days, before randomization. * Patient must not have a history of clinically significant interstitial lung disease or active pneumonitis requiring steroid treatment. Patients with grade 1 radiation pneumonitis or fibrosis are permitted to enroll. * Patient with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association (NYHA) Functional Classification (NYHA Classification). To be eligible for this trial, patient must be class IIB or better. * Patients with history of autoimmune disorders are eligible to enroll only if no disease flares and not requiring any systemic immunosuppressive agents in the past 5 years. Topical or inhaled steroids are permitted. The following are not exclusionary: vitiligo, asthma, endocrine disorders that required only hormone replacement, psoriasis or other skin disorders that do not require systemic treatment, celiac disease controlled by diet alone. * Patients with active primary immunodeficiency are not permitted to enroll. * Prior history of severe or life-threatening events (Common Terminology Criteria for Adverse Events (CTCAE) V6.0 grade ≥ 3) from any immune-related therapy. * Patients with any condition requiring chronic oral corticosteroids is eligible if steroid dose is ≤ 10 mg/day prednisone equivalent. Physiologic replacement doses for adrenal insufficiency are permitted even if dose exceeds 10 mg/day. Inhaled corticosteroids and local steroid injections are permitted. All other uses of steroids must be tapered to ≤ 10 mg/day before randomization. * Patients must not have a history of allogeneic solid organ, allogeneic bone marrow or stem cell transplantation. * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within for 6 months of before randomization are eligible for this trial. * Patient must not have received any live vaccine within 28 days prior to randomization. * Patients with a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent are not eligible. * Any prior therapy with a selective inhibitor of the DLL3 pathway is not permitted. * Any prior therapy with immune-mediated therapy including anti-CTLA-4, anti-PD-1, or anti PD-L1 is not permitted. * Receiving another anti-cancer therapy is not permitted except for hormonal therapy for breast or prostate cancer, topical therapies for cutaneous malignancies, or superficial treatments for non-muscle invasive bladder cancers. * Patients with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of the treatment according to the protocol are not eligible. * Patients may not participate in any other therapeutic clinical trials, including those with other investigational agents not included in this trial during treatment on this study without prior approval from PrECOG.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• PrECOG, LLC.: lead
• Amgen: collaborator

MeSH Terms

Conditions

Small Cell Lung Carcinoma

Interventions

AMG 757; durvalumab

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Ryan Gentzler, MD, MS

  University of Virginia

  STUDY CHAIR

Central Study Contacts

Irini Jorgji, PSM

CONTACT

215-789-3646; PrE0512@precogllc.org

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Open-label, randomized (1:1) to either tarlatamab in combination with durvalumab as consolidation therapy for LS-SCLC after completion of chemotherapy and radiation compared to durvalumab alone.

Study Record Dates

• First Submitted: May 19, 2026
• First Posted: June 9, 2026
• Study Start (Estimated): January 1, 2027
• Primary Completion (Estimated): November 1, 2037
• Study Completion (Estimated): June 1, 2038
• Last Updated: June 9, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share